Tenofovir decreases HSV-2 risk Oral tenofovir-based prophylaxis for HIV also reduced herpes simplex virus-2 transmission. Daily oral tenofovir-based preexposure prophylaxis (PrEP) for HIV also seemed ...

Many viral infections, including HIV, are acquired at mucosal surfaces, necessitating the characterization of the immune environment at these barrier tissues. Unfortunately, clinical HIV research ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. After controlling for sexual behavior and HIV-1 ...

In a recent study published in the Advanced Science journal, researchers assessed the effectiveness of synthetic mucin gels in the inhibition of human immunodeficiency virus-1 (HIV-1) and herpes ...

According to the Centers for Disease Control and Prevention, more than one in six Americans ages 14 to 49 are infected with genital herpes. HSV-2 infection is the most common cause of genital herpes ...

Randomized phase II study with or without induction chemotherapy combined with accelerated high dose radiotherapy and cetuximab in locally advanced unresectable HPV positive squamous cell carcinoma of ...

Genocea’s pipeline of novel clinical stage T cell enabled vaccines includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, ...

HSV-1 usually causes oral herpes, while HSV-2 primarily affects the genitals. You may not know you have herpes because it ...

CAMBRIDGE, Mass--Genocea Biosciences announced today that it has initiated a Phase 1/2a clinical study with its lead candidate, GEN-003. GEN-003 is an investigational vaccine designed to stimulate T ...